Comparative Pharmacology
Head-to-head clinical analysis: DENDRID versus VITRASERT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DENDRID versus VITRASERT.
DENDRID vs VITRASERT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dendrid (idoxuridine) is a pyrimidine nucleoside analog that inhibits viral DNA replication by incorporating into viral DNA and inhibiting thymidylate synthetase, thereby blocking DNA synthesis.
Vitrasert (ganciclovir implant) releases ganciclovir, a nucleoside analog that inhibits cytomegalovirus (CMV) replication by competitively inhibiting viral DNA polymerase (UL54) after intracellular phosphorylation to ganciclovir triphosphate. This results in chain termination and viral DNA synthesis inhibition.
1.5 mg/kg IV every 8 hours; typical adult dose 100 mg IV every 8 hours.
Intravitreal implant containing 0.59 mg fluocinolone acetonide; inserted into the vitreous cavity; releases drug over approximately 36 months; no systemic dosing.
None Documented
None Documented
Terminal elimination half-life is approximately 3-4 hours in adults with normal renal function; prolonged in renal impairment
Terminal half-life of 2.8 hours following intravitreal injection; sustained local levels for 2-3 weeks.
Primarily renal excretion; unchanged drug accounts for 70-90% of elimination; minor biliary/fecal excretion (<10%)
Primarily biliary/fecal (approximately 90%) with minimal renal excretion (<10% unchanged in urine).
Category C
Category C
Antiviral
Antiviral